echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > U.S.-Canada study shows hydroxychloroquine is difficult to prevent new crown infection with placebo

    U.S.-Canada study shows hydroxychloroquine is difficult to prevent new crown infection with placebo

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    , June 5 (UPI) -- The results of randomized controlled trials published Wednesday by U.Sand Canadian scholars showed no significant difference between hydroxychloroquine and placebos in the prevention of new coronavirus infectionThe controversy surrounding the efficacy of hydroxychloroquine has so far been difficultSome scholars believe that the results of the trial published on the 3rd are not enough to completely deny the efficacy of the drug to the new coronavirus, more and more extensive research to further verifyThe study, published Wednesday in the New England Journal of Medicine, was widely watched because randomized controlled trials were considered "goldenstandard" to determine clinical trial results,AFP reportedPrevious studies on hydroxychloroquine were mostly "observational" and it was difficult to draw firm conclusions because of the existence of multiple uncontrollable factorsThe double-blind trial, conducted in the United States and Canada, recruited 821 adults with medium- to high-risk infections, with an average age of 40They are relatives living with newly diagnosed patients, or who work in health care and first aid, having been in contact with patients when they were not wearing masks or goggles, less than two metres away and for more than 10 minutesWhen they took part in the trial, they showed no signs of new crownsThe researchers used couriers to randomly distribute hydroxychloroquine or folic acid nutrients to participants, requiring them to start taking the drug within four days of exposure to the new coronavirus and take it for five daysThe researchers then looked at the participants for the new coronavirus by testing results or clinical symptomsAfter 14 days of the trial, 49 of the 414 people who took hydroxychloroquine were infected, or 11.83 per cent, and 58 of the 407 people who took the placebo were infected, accounting for 14.25 per centThe difference of about 2.4 percentage points was not considered statistically significantDavid Bolwell, an infectious disease scholar at the University of Minnesota and one of the report's lead authors, said hydroxychloroquine is "basically unpreventable." Lead author Todd Lee, an associate professor at McGill University in Canada, said their study showed that hydroxychloroquine had the same effect as a placebo for post-exposure prevention of infectionThe results also showed that 40.1% of people who took hydroxychloroquine experienced side effects such as nausea and stomach pain, while 16.8% of those who took a placebo experienced side effectsHowever, according to Reuters, the trial did not find that hydroxychloroquine could cause serious side effects such as heart problemshydroxychloroquine is often used to treatdiseases such as malaria, lupus and rheumatoid arthritisU.SPresident Donald Trump said in March that taking hydroxychlorophychasi and azithromycin was "quite likely" to play a "turnaround" role in the fight against the new coronavirusHe had been taking hydroxychloroquine, zinc tablets and vitamin D for two weeks after two White House staffers were diagnosedThe president's doctor announced on the 3rd that the latest medical examination results show that the above-mentioned medication did not have a negative effectHowever, Reuters reported that more than 20 percent of the participants took zinc tablets on their own in an effort to enhance immunity, but with no significant effectSeveral clinical trials have been suspended because of previous concerns from some health regulators and researchers about the safety risks of hydroxyl quinsoAccording to Bolwell, the two sides of the argument that hydroxyl chloride is "dangerous" and "useful" are "not true"Myron Cohen of the University of North Carolina at Chapel Hill, usa, wrote for the New England Journal of Medicine that the results did not provide a clear conclusion and instead caused more controversyMartin Landray, a professor at the University of Oxford who was not involved in the trial, also told AFP that the trial was "too small" to be conclusive and that more research was needed to determine whether hydroxychloroquine had a "moderate" effectBorwell has now completed another trial of whether hydroxychloroquine can treat the new crown and is evaluating the resultsThe Mahilon-Oxford Institute of Tropical Medicine in Bangkok, Thailand, is preparing to recruit about 40,
    medical care workers from around the world to conduct clinical trials to determine whether hydroxychloroquine can prevent a new crown, the Guardian reported   According to the Associated Press, the results of the trial released on the 3rd there are limiting factors The researchers recruited participants online and on social media, asking them to self-report symptoms without a doctor tracking their condition Moreover, the researchers determined that some of the test subjects who were infected with the virus were not tested for the virus and were "diagnosed" simply because they had symptoms such as fever and cough In addition, not all participants took the drugs strictly as required   The British Lancet magazine on Tuesday "expressed concern" about a previously published study of hydroxychloroquine, citing strong doubts about the data The study analyzed the medical records of nearly 15,000 people and showed that hydroxychloroquine can trigger complications such as heart disease, increasing the risk of death The World Health Organization announced after the publication of the study suspended the exploration of the new crown treatment drug program in the "solidarity trial" of the international project hydroxychloroquine branch trial, 3 said the relevant trials can continue (Ocean) (Xinhua News Agency)
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.